Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2021-09-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
安信证券股份有限公司关于奥锐特药业股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring institution regarding the listing and circulation of restricted shares from a company's initial public offering. It references regulatory approvals, share lock-up periods, shareholder commitments, and the number of shares becoming freely tradable. The document is relatively short (2666 characters) and focuses on the compliance and procedural aspects of share circulation rather than presenting financial data or detailed financial statements. It does not contain financial results, management discussion, or audit information. It is essentially an official opinion or announcement related to share circulation compliance and lock-up release. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and does not qualify as a full financial report or other specific filing types.
2021-09-14 Chinese
奥锐特药业股份有限公司首次公开发行部分限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the dates of circulation, shareholder commitments, and confirmations from the sponsoring securities firm. The document does not contain financial statements or performance data but rather informs the market and shareholders about the change in share status and compliance with regulatory requirements. This type of document fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement about share circulation and compliance, not a financial report or earnings release.
2021-09-14 Chinese
奥锐特药业股份有限公司2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report on the official website. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 2554 characters, which is sufficient for a summary but not a full annual report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-30 Chinese
奥锐特药业股份有限公司第二届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 奥锐特药业股份有限公司 (Aoruite Pharmaceutical Co., Ltd.). It details the meeting date, attendance, and voting results on several agenda items, including approval of the 2021 half-year report, a special report on fundraising usage, and a proposal on using idle funds for entrusted financial management. The document references the actual half-year report and other detailed reports published elsewhere, indicating this document itself is not the report but an announcement of board decisions. The document length is short (1048 characters), and it serves as a meeting resolution announcement rather than a full financial report or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2021-08-30 Chinese
奥锐特药业股份有限公司关于使用闲置自有资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding the use of idle self-owned funds for entrusted financial management. It details the amount, purpose, risk control, and approval procedures related to the company's cash management activities. The document includes financial figures but does not present comprehensive financial statements or detailed financial analysis. It is a disclosure about financing activities related to cash management and investment of idle funds, not a full financial report or earnings release. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage.
2021-08-30 Chinese
奥锐特药业股份有限公司第二届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the second Supervisory Board of 奥锐特药业股份有限公司. It includes details about the meeting's convening, attendance, and the approval of several proposals, including the review of the company's 2021 semi-annual report, a special report on the use of raised funds, and the use of idle funds for entrusted financial management. The document does not contain the actual semi-annual report or detailed financial statements but refers to these reports being published elsewhere (e.g., Shanghai Stock Exchange website and newspapers). The document is relatively short (1505 characters) and serves as an official announcement of meeting resolutions and approvals rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for announcements and compliance documents that do not contain full reports or detailed financial data.
2021-08-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.